Document Classification

Section Type: RESULTS

Text: In subjects that did not change the intensity of the baseline diabetes therapy (72 %), and that were on any one or two OADs (ALL), or on metformin with or without another OAD (Met/OAD), or on metformin plus sulfonylurea (Met/SU), the HbA1c change for bromocriptine-QR versus placebo was -0. 47 versus +0. 22 (between group delta of -0. 69, P <. 0001), -0. 55 versus +0. 26 (between group delta of -0. 81, P <. 0001) and -0. 63 versus +0. 20 (between group delta of -0. 83, P <. 0001) respectively, after 24 weeks on therapy.